Filing Flows › Castle Biosciences (CSTL) › Dermatologic revenue
Castle Biosciences (CSTL) Dermatologic revenue by quarter
Castle Biosciences' Dermatologic revenue was $47.9M in Q3 2026 (third quarter 2026), -2% from Q2 2026. Over the last 7 quarters it ranged from $41.1M (Q1 2026) to $63.0M (Q1 2025).
| Quarter | Dermatologic revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $47.9M | -2% | -1% |
| Q2 2026 | $48.7M | +18% | -13% |
| Q1 2026 | $41.1M | -15% | -35% |
| Q4 2025 | $48.6M | +0.1% | — |
| Q3 2025 | $48.5M | -14% | — |
| Q2 2025 | $56.3M | -11% | — |
| Q1 2025 | $63.0M | — | — |
Q3 2026 at a glance
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Castle Biosciences' Dermatologic revenue?
Castle Biosciences' Dermatologic revenue was $47.9M in Q3 2026 (third quarter 2026), -2% from Q2 2026.
How has Castle Biosciences' Dermatologic revenue changed?
Over the last 7 quarters it ranged from $41.1M (Q1 2026) to $63.0M (Q1 2025).